Four weeks versus six weeks of ampicillin plus ceftriaxone in Enterococcus faecalis native valve endocarditis: A prospective cohort study by Ramos-Martínez, Antonio et al.
RESEARCH ARTICLE
Four weeks versus six weeks of ampicillin plus
ceftriaxone in Enterococcus faecalis native
valve endocarditis: A prospective cohort study
Antonio Ramos-Martı́nezID
1,2☯*, Juan Manuel Pericàs3☯, Ana Fernández-CruzID1,
Patricia Muñoz4,5, Maricela Valerio4, Martha Kestler4, Miguel Montejo6, M.
Carmen Fariñas7, Dolores SousaID8, Fernando Domı́nguez9, Guillermo Ojeda-Burgos10,
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Abstract
Enterococcus faecalis infective endocarditis (EFIE) is a severe disease of increasing inci-
dence. The objective was to analyze whether the outcome of patients with native valve EFIE
(NVEFIE) treated with a short course of ampicillin plus ceftriaxone (4wAC) was similar to
patients treated according to international guidelines (6wAC). Between January 2008 and
June 2018, 1,978 consecutive patients with definite native valve IE were prospectively
included in a national registry. Outcomes of patients with NVEFIE treated with 4wAC were
compared to those of patients who received 6wAC. Three hundred and twenty-two patients
(16.3%) had NVEFIE. One hundred and eighty-three (56.8%) received AC. Thirty-nine
patients (21.3%) were treated with 4wAC for four weeks and 70 patients (38.3%) with
6wAC. There were no differences in age or comorbidity. Patients treated 6wAC presented a
longer duration of symptoms before diagnosis (21 days, IQR 7–60 days vs. 7 days, IQR
1–22 days; p = 0.002). Six patients presented perivalvular abscess and all of these received
6wAC. Surgery was performed on 14 patients (35.9%) 4wAC and 34 patients (48.6%)
6wAC (p = 0.201). In-hospital mortality, one-year mortality and relapses among 4wAC and
6wAC patients were 10.3% vs. 11.4% (p = 0.851); 17.9% vs. 21.4% (p = 0.682) and 5.1%
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vs. 4.3% (p = 0.833), respectively. In conclusion, a four-week course of AC may be consid-
ered as an alternative regimen in NVEFIE, notably in patients with shorter duration of symp-
toms and those without perivalvular abscess. These results support the performance of a
randomized clinical trial to evaluate the efficacy of this short regimen.
Introduction
Enterococcus faecalis is the third most common cause of infective endocarditis (IE) [1]. E. fae-
calis infective endocarditis (EFIE) is characterized by its increasing incidence and tendency to
affect elderly patients and those with multiple comorbidities [2, 3].
E. faecalis is remarkably resistant to antibiotic-induced eradication, which requires treat-
ment with synergistic antibiotic combinations. Currently, the combination of ampicillin plus
ceftriaxone (AC) is the antibiotic treatment of choice for EFIE in several settings, and espe-
cially so in Spain [4–7]. With respect to treatment duration, international guidelines recom-
mend a 6 week-course of AC for native valve EFIE [8, 9]. However, these same guidelines
accept the use of other antibiotic combinations (e.g. a beta-lactam plus gentamicin) for four
weeks when the duration of symptoms is shorter than 3 months. Evidence is lacking from
studies comparing the efficacy of shorter courses of AC with respect to the recommended
duration of 6 weeks for the treatment of EFIE. However, the use of a shortened course of AC is
relatively common for treating non-complicated native EFIE.
The aim of the present study was to analyze whether the clinical outcomes of patients suf-
fering from native valve EFIE treated with a short-course regimen of AC (four weeks) were
similar to those of patients treated for the recommended six weeks.
Methods
Between January 2008 and June 2018, 3,830 consecutive patients were prospectively included
in the “Spanish Collaboration on Endocarditis—Grupo de Apoyo al Manejo de la Endocarditis
Infecciosa en España (GAMES)”, a registry maintained by 27 Spanish hospitals. Multidisci-
plinary teams completed standardized case report forms with IE episode and follow-up data
that included clinical, microbiological and echocardiographic sections [10, 11]. The study was
approved by regional ethics committee (Comité Ético de Investigación Clı́nica Regional de la
Comunidad de Madrid with approval code: 07/18). Written informed consent was obtained
from all patients.
Definitions
IE was defined according to the modified Duke criteria [12]. Microbiological diagnoses were
determined by blood or valve culture and/or molecular techniques [10]. Transthoracic (TTE)
and transesophageal echocardiography (TEE) were performed on patients with clinical or
microbiological suspicion of IE according to European guidelines, or to diagnose valve dys-
function and intracardiac complications such as abscess, vegetation, pseudoaneurysm and fis-
tula [8, 13, 14]. Hospital-acquired IE was defined as either IE manifesting >48 hours after
hospital admission or IE acquired in association with a significant invasive procedure per-
formed within 6 months prior to diagnosis. The EuroScore and LogEuroScore were used to
assess surgical risk [15]. All the necessary variables were collected to calculate the Charlson
Comorbidity Index [16].
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For the purposes of this study, patients with definite native valve EFIE were selected from
the GAMES database. Patients who only met possible Duke IE criteria as well as right-sided IE
cases without concomitant left-side infection were excluded from the study. Fourteen patients
had been included in a previous investigation [17]. Patients classified as treated with AC did
not receive gentamicin at any time. The dose of ampicillin was 12 grams per day in 4 or 6
doses (adjusted for renal function) and ceftriaxone was 2 g every 12 hours, both intravenously.
The decision about the duration of treatment was taken by the responsible physicians at the
beginning of the treatment but could also be taken during the patient’s clinical evolution.
Patients were classified according to the length of treatment: patients who received 28 ± 4 days
of AC antibiotic treatment were included in the short-course group, whereas patients who
received 42 ± 6 days of treatment were included in the long- or conventional-treatment group
The date of the first negative blood culture was considered in calculating the duration of treat-
ment. Patients with a length of treatment that did not fit any of these definitions were
excluded.
In-hospital mortality was defined as death, irrespective of cause, that occurred during hos-
pital admission in patients who had completed antibiotic treatment. Patients who died before
completing their allotted course of treatment were excluded from the analysis. The Cockcroft-
Gault equation was used to calculate creatinine clearance [18]. Pre-episode renal insufficiency
was defined as plasma creatinine over 1.4 mg/dl. New or worsening renal insufficiency during
the IE episode was defined as an increase of baseline creatinine clearance or plasma creatinine
by at least 25%, or creatinine levels over 1.4 mg/dl when a previous analysis had been normal.
Persistent bacteremia was defined as positive blood cultures more than seven days after effec-
tive antibiotic therapy. Endocarditis relapse was defined a new episode of EFIE during the first
year after finishing treatment.
Data from patients with native valve EFIE were analyzed, including clinical manifestations
at IE presentation, pathogens, therapy, morbidity and mortality during hospitalization and
during the first year after hospitalization. Follow-up information was obtained via pro-
grammed medical follow-up, by telephone or through written or electronic correspondence
with the patients or their primary-care physician.
Statistical analysis
Quantitative variables were reported as median and interquartile range (IQR), qualitative vari-
ables were reported as figures and percentages. Continuous variables were compared using the
Mann- Whitney test, because they had a non-normal distribution. Categorical variables were
summarized as percentages and continuous variables as medians and interquartile ranges. Cat-
egorical variables were compared using the chi-square test (or Fisher’s exact test where neces-
sary). Survival analysis was performed using Kaplan-Meier, and survival curves (showing the
survival of patients from diagnosis until the end of the first year) were compared using the log-
rank test. Given the limited number of patients in the study, no multivariate logistic regression
analyses were performed. A 2-sided P<0.05 was considered to be statistically significant. All
statistical analyses were performed using SPSS software version 18 (SPSS Inc., Chicago, Illi-
nois, USA).
Results
Three hundred and twenty-two patients (16.3%) had definite native valve EFIE. Most patients
received AC (183 patients, 56.8%), while ampicillin plus gentamicin (AG) was administered to
73 patients (22.7%), and 66 patients (20.5%) were treated with other options. The patient flow-
chart is shown in Fig 1.
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Among the subset of 183 patients treated with AC, 39 patients were treated exclusively with
these antibiotics for four weeks and 70 patients for six weeks. The differences between the short
treatment (four weeks) and conventional treatment group (six weeks) are shown in Tables 1
Fig 1. Chart showing patients presenting with definite native valve infective endocarditis according to etiology and treatment (GAMES cohort).
https://doi.org/10.1371/journal.pone.0237011.g001
Table 1. Baseline characteristics of patients with native valve E. faecalis infective endocarditis (EFIE) treated with
ampicillin plus ceftriaxone according to the duration of antibiotic treatment.
4 weeks (n = 39) 6 weeks (N = 70) P
Age (years) 75 (67–80) 72 (63–78) 0.222
Male gender 26 (66.7) 50 (71.4) 0.604
Hospital-acquired 10 (25.6) 22 (31.4) 0.676
Non-nosocomial health-care related 4 (10.2) 10 (14.2) 0.761
Diabetes mellitus 11 (28.2) 20 (28.6) 0.404
Coronary disease 8 (20.5) 22 (31.4) 0.284
Peripheral arterial disease 3 (7.6) 8 (11.4) 0.775
Cerebrovascular disease 6 (15.4) 5 (7.1) 0.15
Previous renal failure 11 (28.2) 17 (24.3) 0.653
Chronic liver disease 4 (10.3) 7 (10.0) 0.931
Injecting drug user 0 1 (1.4) 0.648
Neoplasia 9 (23.7) 14 (20.0) 0.655
Age-adjusted Charlson Comorbidity Index (points) 6 (4–7) 6 (4–8) 0.716
Quantitative variables are reported with median and interquartile range.
https://doi.org/10.1371/journal.pone.0237011.t001
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and 2. In terms of baseline conditions, age and comorbidity were similar in patients treated for
four weeks and in those treated for six weeks. Chronic liver disease was present in 10.3% (n = 4)
of patients receiving short treatment and 10% (n = 7) of patients receiving long treatment. Six
patients presented perivalvular abscess and all of these were treated for six weeks (P = 0.072,
Table 2). With regard to prognosis related to echocardiographic findings, the presence of peri-
valvular abscess, valve perforation or a vegetation size greater than 10 mm was associated with
an increased risk of recurrence and increased mortality during admission or at one year. Sur-
gery was performed on 14 patients (35.9%) receiving short treatment and on 34 patients
(48.6%) receiving long treatment (P = 0.201).
Outcomes were similar in the two groups: there were no differences regarding the incidence
of persistent bacteremia, embolisms, relapses, in-hospital mortality or mortality during the
first year (Table 2, Fig 2). There were five relapses, two in 4wAC group (both during the first
six months after treatment) and three in the 6wAC group (both during the first six months
after treatment). Two patients had a history of liver cirrhosis (one in each group) and one of
Table 2. Clinical presentation an outcome of patients with native valve E. faecalis infective endocarditis (EFIE) treated with ampicillin plus ceftriaxone according
to the duration of antibiotic treatment.
4 weeks (n = 39) 6 weeks (N = 70) P
Site of infection
Mitral 22 (56.4) 48 (68.6) 0.204
Aortic 17 (43.6) 33 (47.1) 0.721
Tricuspid 1 (2.6) 5 (7.1) 0.417
Pulmonary 0 0 -
Duration of symptoms before diagnosis (days) 7 (1–22) 21 (7–60) 0.002
Septic shock 2 (5.1) 4 (5.7) 0.922
Persistent bacteremia 6 (15.4) 10 (14.7) 0.925
CNS vascular events 5 (12.8) 12 (17.1) 0.551
Embolism 8 (20.5) 16 (22.9) 0.717
Heart failure 18 (46.2) 34 (48.6) 0.809
New or worsening renal insufficiency 10 (25.6) 20 (28.6) 0.743
Echocardiographic findings
Vegetation 34 (87.1) 62 (88.6) 0.925
Median size vegetation (IQR) 12 (8–18) 14 (7–20) 0.471
Perivalvular abscess 0 6 (8.6) 0.060
Valve perforation or rupture 4 (10.3) 17 (24.3) 0.060
Pseudoaneurysm 1 (2.6) 3 (4.3) 0.549
Intracardiac fistula 0 0 -
Surgical indication 17 (43.6) 45 (64.3) 0.085
Surgery performed 14 (35.9) 34 (48.6) 0.201
Duration of antibiotic treatment 32 (28–42) 42 (42–45) <0.01
Treatment with ampicillin (days) 29 (28–32) 42 (41–45) <0.01
Treatment with ceftriaxone (days) 29 (28–30) 43 (41–45) <0.01
Hospital stay (days) 40 (27–54) 51 (44–66) 0.001
EFIE relapse1 2 (5.1) 3 (4.3) 0.833
In-hospital mortality 4 (10.3) 8 (11.4) 0.851
One-year mortality 7 (17.9) 15 (21.4) 0.682
CNS: central nervous system. Quantitative variables are reported with median and interquartile range.
1See text for relapses.
https://doi.org/10.1371/journal.pone.0237011.t002
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them, who suffered two relapses, has already been communicated in a previous publication
[17]. None of the cases had paravalvular abscesses.
Adverse effects attributable to ceftriaxone were leukopenia (two patients, both 6wAC
group), glomerulonephritis (one patient, 6wAC group), diarrhea associated with antibiotics
without Clostridiodes difficile infection (one patient, 4wAC group). Of the 74 patients who
received CA for more than 50% of the time but did not meet the criteria for inclusion in the 4-
or 6-week treatment groups, 29 patients received at least 4 weeks of treatment. In these
patients, mortality during admission was 5.5% (2 patients), mortality during the first year was
22.2% (8 patients) and no cases of recurrence were recorded
Discussion
This is the first cohort study to primarily focus on the prognosis of patients with EFIE treated
with a short course of AC. It shows that the prognosis of patients with native valve EFIE treated
for 4 weeks with AC is similar to those treated for 6 weeks. However, some differences in the
Fig 2. One-year survival according to duration of the treatment in a series of EFIE.
https://doi.org/10.1371/journal.pone.0237011.g002
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clinical characteristics of patients between the 4-week and 6-week groups may limit the appli-
cability of this result to selected cases.
Both AG and AC have been shown to be synergistic combinations in vitro and effective
antibiotic treatments in vivo for EFIE [1, 4, 5, 19, 20]. However, guidelines recommend differ-
ent durations for each of these combinations when treating native valve EFIE: four or six
weeks for AG and six weeks for AC [8, 9]. The median duration of treatment with AC used in
the first two studies to compare the efficacy of AC versus AG was six weeks [4, 21]. As a result,
international guidelines incorporated the 6-week protocol as the universal duration for courses
of AC to treat both native and prosthetic valve EFIE [8, 9]. The study by Fernandez-Hidalgo
et al confirmed that AC given for a median of six weeks was an effective therapy for EFIE and
safer than four to six weeks of ampicillin plus gentamicin. However, this study did not clarify
whether four weeks of ampicillin plus ceftriaxone would be effective against uncomplicated
native valve EFIE [4]. A previous single-center study compared 4-week with 6-week treatments
for EFIE by analyzing patients treated with AC and AG according to the duration of antibiotic
treatment [17]. Neither that study nor ours detected higher mortality (either during hospital
admission or the first year) associated with short-course treatments. However, in the afore-
mentioned study, relapses were more frequent with short-course treatments (with either AC
or AG) when analyzing both native and prosthetic valves. Interestingly, relapses were no
higher when analyzing only patients with native valve EFIE who were treated for four weeks. It
is also worth noting that the relapse rate in patients who received treatment for four weeks in
our study (5%) was similar to the other series of EFIE based on a treatment with AC lasting at
least six weeks (3–8%) [1, 4, 5, 21].
The propensity of patients with chronic liver disease to develop enterococcal invasive and
relapsing infections should be taken into consideration when deciding the appropriate length
of EFIE treatment [17, 22]. Among the patients included in this study, only 10% had chronic
liver disease, which limits significant conclusions in this regard. Two of the patients who
relapsed had chronic liver disease. In any case, considering that these patients have a high sur-
gical risk, it is of paramount importance to try to minimize the risk of relapse, since this could
leave surgery as the patient’s only recourse. Consequently, we have to express our doubts that a
four-week regimen would be recommendable for cirrhotic patients.
Seminal studies that provided evidence for establishing the length of EFIE treatment with
beta-lactams plus aminoglycosides showed that longer periods of symptoms have generally
been associated to an increased risk of relapse and death [23, 24]. It was suggested that longer
illness is due to enterococci that grow relatively slowly and produce dense vegetations which
are less accessible to antimicrobial agents [23]. Despite the fact that none of studied patients
presented symptoms for more than 3 months prior to diagnosis, the duration of symptoms
was longer in those who received six weeks compared to those who received four weeks of
treatment. It is possible that long treatments were selected for patients with longer duration of
symptoms due to its relationship with poor prognoses [23]. Therefore, our results may not
substantiate the use of short courses in patients with longer duration of symptoms.
All patients with perivalvular abscess received six weeks of AC, which is an expected result.
It would be seen as unsafe to select a short course of treatment of either AG or AC in these
patients who also had indications for surgical treatment [25]. In our series, patients with valve
perforation or rupture and those who underwent surgery also tended to receive longer treat-
ment. These clinical differences between the two groups could preclude recommending a
short course of AC in patients with some of the above-mentioned characteristics.
We found a significant shortening of the hospital stay in short course treated patients. The
saving in patient complications and hospital stay on account of short-course treatment has
already been a common goal of various IE studies. [26, 27]. The potential protective effect of
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shorter courses of beta-lactams, ranging from lower rates of antibiotic-related toxicity to the
risk of suffering from C. difficile infections or for the selection of vancomycin-resistant E. fae-
cium [28–30].
Limitations
Some limitations of the study should be noted. The main limitation is that it was not a ran-
domized clinical trial, which could have determined that the probability of receiving a short or
long treatment depended on certain patient characteristics. Analysis based on "intention to
treat" could not be done because this variable was not collected in the study. The duration of
treatment actually completed by each patient was primarily considered. In addition, most of
the institutions participating in the GAMES registry are tertiary university hospitals that
receive a substantial number of patients from other centers (most of which do not have facili-
ties for cardiac surgery), which could represent a certain selection bias. And finally, the statisti-
cal power of this study is limited due to the low number of patients included. This limitation
may have prevented detecting a difference in prognosis in relation to the duration of treat-
ment. These limitations induce caution when drawing conclusions regarding the efficacy of
short-course AC treatments. In spite of this limitations, the importance of the pathology stud-
ied and the difficulties in carrying out clinical trials in this type of patient allow, in our opinion,
to anticipate the possibility of a short treatment for some selected patients.
Conclusions
In conclusion, due to very similar rates of relapse and mortality in patients with native valve
EFIE treated with AC for 4 and 6 weeks, this study suggests that a short course of AC might be
sufficient to treat native valve EFIE. Due to clinical differences between the two groups studied,
a short course of antibiotics cannot be recommended for patients presenting with longer dura-
tion of symptoms or perivalvular abscess. Further research is required to validate these results
as well as to elucidate whether short-course treatments should be recommended to treat all
native valve EFIE, or only to treat selected patients with specific features that present a more
favorable prognosis which is still to be defined. This study could be the rationale for perform-
ing a randomized clinical trial in non-complicated native valve EFIE.
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Ángeles Rodrı́guez Esteban, Raquel Rodrı́guez Garcı́a, Mauricio Telenti Asensio; Hospital
Clı́nic-IDIBAPS, Universidad de Barcelona, (Barcelona): Manuel Almela, Juan Ambrosioni,
Manuel Azqueta, Mercè Brunet, Marta Bodro, Ramón Cartañá, Carlos Falces, Guillermina
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Román Calvo Jambrina, Marina de Cueto, Juan Gálvez Acebal, Irene Méndez, Isabel Morales,
Luis Eduardo López-Cortés; Hospital Universitario Virgen del Rocı́o, (Sevilla): Arı́stides de
Alarcón, Emilio Garcı́a, Juan Luis Haro, José Antonio Lepe, Francisco López, Rafael Luque;
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(Vitoria): Andrés Canut Blasco, José Cordo Mollar, Juan Carlos Gainzarain Arana, Oscar Gar-
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